pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›MOUNJARO
drug · protein
save

MOUNJARO

updated 6mo ago
/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 6
  • drugtirzepatide112 co-mentions · 40 sources
  • drugZEPBOUND112 co-mentions · 40 sources
  • tagApproval96 co-mentions · 24 sources
  • companyEli Lilly and Co48 co-mentions · 24 sources
  • tagRecall16 co-mentions · 16 sources
  • drugcyanocobalamin2 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

targets

Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying MOUNJARO

  • phase4A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetesactive not recruitingn=794
  • phase1Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinibrecruitingn=30
  • phase3A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetesnot yet recruitingn=1,000
  • phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medicationrecruitingn=60
  • phase3Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)not yet recruitingn=150
  • phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorderrecruitingn=105
  • phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)recruitingn=300
  • phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitorcompletedn=1,024

News(10)

  • Novo’s CagriSema drives more than 20% weight loss at lower doses
    As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…
    biospace · 14h ago
  • STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
    During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year
    stat · 14h ago
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 3d ago
  • STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
    A deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lilly
    stat · 3d ago
  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 3d ago
  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 4d ago
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 4d ago
  • STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
    The FDA has shelved the fast-track drug review initiative launched in June 2025 by former Commissioner Marty Makary
    stat · 4d ago
  • STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
    Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:
    stat · 5d ago
  • STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
    Incoming Democratic chairs of key congressional committees have taken a new step toward investigating most-favored nation drug pricing agreements
    stat · 5d ago
view all news mentions →
brand
MOUNJARO
trade names
Mounjaro, Mounjaro (autoinjector), Zepbound, Zepbound (autoinjector)
generic
TIRZEPATIDE
MOA
12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
indication
1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?